Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UX6Z
|
|||
| Drug Name |
Heparin Sodium
|
|||
| Synonyms |
(2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container
Click to Show/Hide
|
|||
| Indication | Coagulation defect [ICD-11: 3B10.0; ICD-10: I80-I82] | Approved | [1] | |
| Deep vein thrombosis [ICD-11: BD71] | Approved | [2] | ||
| Therapeutic Class |
Cardiovascular Agents
|
|||
| Company |
Hospira Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C26H42N2NaO37S5+
|
|||
| Canonical SMILES |
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
|
|||
| InChI |
1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1
|
|||
| InChIKey |
JRTRSJGZMRQDHI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| ADReCS Drug ID | BADD_D01060 ; BADD_D01061 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Antithrombin-III (ATIII) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4214). | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.